JOURNEY MEDICAL CORPOR

6.8300

12-May-25 15:45:00

15 minutes delayed

Stocks

-0.0500

-0.73%

Today's range

6.6862 - 7.0990

ISIN

N/A

Source

NASDAQ

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

07 May 2025 15:01:25 By Nasdaq GlobeNewswire
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

23 Apr 2025 08:45:10 By NetDania Notify
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

22 Apr 2025 15:02:52 By NetDania Notify
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

04 Apr 2025 08:45:28 By NetDania Notify
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

01 Apr 2025 15:01:16 By Nasdaq GlobeNewswire
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

26 Mar 2025 15:01:00 By Nasdaq GlobeNewswire
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

24 Mar 2025 07:30:00 By Nasdaq GlobeNewswire
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

19 Mar 2025 15:01:56 By Nasdaq GlobeNewswire
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

12 Mar 2025 07:30:49 By Nasdaq GlobeNewswire
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

05 Mar 2025 15:01:06 By Nasdaq GlobeNewswire
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

04 Mar 2025 15:01:50 By Nasdaq GlobeNewswire
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

23 Jan 2025 07:30:42 By Nasdaq GlobeNewswire
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12 Nov 2024 15:01:12 By Nasdaq GlobeNewswire
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

04 Nov 2024 06:00:53 By Nasdaq GlobeNewswire
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

25 Oct 2024 07:30:35 By Nasdaq GlobeNewswire
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

03 Oct 2024 07:30:23 By Nasdaq GlobeNewswire
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

09 Sep 2024 07:30:35 By Nasdaq GlobeNewswire
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 07:15:03 By Nasdaq GlobeNewswire
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

12 Aug 2024 15:01:35 By Nasdaq GlobeNewswire
Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

06 Aug 2024 15:01:38 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.